Last reviewed · How we verify
Treatment of osteoporosis in postmenopausal women at high risk of fracture
Approved treatments
- Duavee · Pfizer
DUAVEE pairs conjugated estrogens with bazedoxifene, which bind to and activate estrogen receptors α and β.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Treatment of osteoporosis in postmenopausal women at high risk of fracture patent landscape — cliff calendar, originator estates, attackable patents
- Treatment of osteoporosis in postmenopausal women at high risk of fracture treatment landscape brief
- Treatment of osteoporosis in postmenopausal women at high risk of fracture treatment updates RSS
Frequently asked questions about Treatment of osteoporosis in postmenopausal women at high risk of fracture
What drugs treat Treatment of osteoporosis in postmenopausal women at high risk of fracture?
Tracked treatments include Duavee.
What is the treatment for Treatment of osteoporosis in postmenopausal women at high risk of fracture?
Standard treatment for Treatment of osteoporosis in postmenopausal women at high risk of fracture includes Duavee. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Treatment of osteoporosis in postmenopausal women at high risk of fracture patent cliff · Treatment of osteoporosis in postmenopausal women at high risk of fracture CI report
- Treatment: Duavee · Pfizer
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing